West Pharma Q4 adj EPS $2.04, +12.1% YoY; guides FY2026 $7.85-$8.20

WEST PHARMACEUTICAL SERVICES INC

2025-FY EPS reported $6.79 vs consensus $1.85 ▲ beat (+266.9%)

Q4 net sales $805M (+7.5% reported, +3.3% organic); HVP Components $389.8M (+20.3%, +15.1% organic).
Full-year 2025: net sales $3.074B (+6.3%); diluted EPS $6.79 (+1.5%), adj-diluted EPS $7.29 (+8.0%).
FY2026 guidance: net sales $3.215B-$3.275B (4.6%-6.5% growth); adj-diluted EPS $7.85-$8.20 (+7.7%-12.5%).
Operating cash flow $754.8M (+15.5%); free cash flow $468.9M (+69.6%); repurchased 552,593 shares for $134M.
Expects mid-2026 close of SmartDose 3.5mL sale to AbbVie; device generated $55M in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.